The role of the opioid system in decision making and cognitive control: A review by Steenbergen, H. van et al.
SPECIAL ISSUE/REWARD SYSTEMS, COGNITION,AND EMOTION
The role of the opioid system in decision making and cognitive
control: A review
Henk van Steenbergen1,2 & Marie Eikemo3,4 & Siri Leknes4
Published online: 8 April 2019
# The Author(s) 2019
Abstract
The opioid system regulates affective processing, including pain, pleasure, and reward. Restricting the role of this system to
hedonic modulation may be an underestimation, however. Opioid receptors are distributed widely in the human brain, including
the more Bcognitive^ regions in the frontal and parietal lobes. Nonhuman animal research points to opioid modulation of
cognitive and decision-making processes. We review emerging evidence on whether acute opioid drug modulation in healthy
humans can influence cognitive function, such as how we choose between actions of different values and how we control our
behavior in the face of distracting information. Specifically, we review studies employing opioid agonists or antagonists together
with experimental paradigms of reward-based decision making, impulsivity, executive functioning, attention, inhibition, and
effort. Although this field is still in its infancy, the emerging picture suggests that the mu-opioid system can influence higher-level
cognitive function via modulation of valuation, motivation, and control circuits dense in mu-opioid receptors, including
orbitofrontal cortex, basal ganglia, amygdalae, anterior cingulate cortex, and prefrontal cortex. The framework that we put
forward proposes that opioids influence decision making and cognitive control by increasing the subjective value of reward
and reducing aversive arousal. We highlight potential mechanisms that might underlie the effects of mu-opioid signaling on
decision making and cognitive control and provide directions for future research.
Keywords Opioid system . Cognitive control . Decision making . Executive function . Value-based choice . Reward . Drugs .
Mu-opioid receptors . Affect . Mood .Morphine . Hedonic states
Introduction
Pleasure and pain are powerful motivators that determine a
great deal of our behavior in daily life. Opioid drugs are
known to dampen pain and increase pleasure (Kringelbach
& Berridge, 2009; Leknes & Tracey, 2008). The subjective
reports of people taking opioids for pain relief or recreation
(De Quincey, 2000) have been corroborated by findings that
rodents will work to obtain an opioid but also to avoid opioid
blockade (Mucha & Iversen, 1984). Accordingly, many influ-
ential theories describe the opioid system as the brain’s regu-
lator of affective states (Barbano & Cador, 2007; Berridge &
Kringelbach, 2015; Koob & Le Moal, 2001).
Opioid drugs are the Bgold standard^ treatment for periop-
erative pain, for example. These drugs also dampen other
aversive experiences, such as the sensation of breathlessness
(Hayen et al., 2017), psychosocial stress (Bershad, Jaffe,
Childs, & de Wit, 2015; Bershad, Miller, Norman, & de Wit,
2018), and depressive symptoms (Peciña et al., 2018).
Evidence from nonhuman animal studies highlights the im-
portance of the opioid system in regulating not just aversive
experiences but also motivation and Bliking^ of food (Baldo,
2016; S. Peciña & Smith, 2010), social contact (Loseth,
Ellingsen, & Leknes, 2014), and other rewards (Laurent,
Morse, & Balleine, 2015). The available human literature is
still limited but is suggestive of a similar hedonic regulation
by the human opioid system. A recent review of positron
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emission tomography (PET) studies with opioid receptor-
specific tracers posit a central role of the opioid system for
positive affective states (Nummenmaa & Tuominen, 2017).
Drug studies in both human and nonhuman animals show that
blocking opioids reduces food pleasantness and consumption,
especially for high-calorie foods (Drewnowski, Krahn,
Demitrack, Nairn, & Gosnell, 1992; Eikemo et al., 2016;
Price, Christou, Backman, Stone, & Schweinhardt, 2016;
Yeomans, 1995; Yeomans & Gray, 2002).
For aversive stimuli, blocking opioid signaling can en-
hance or maintain responses in aversive learning tasks
(Eippert, Bingel, Schoell, Yacubian, & Büchel, 2008;
Haaker, Yi, Petrovic, & Olsson, 2017). Opioid blockade can
also increase the aversiveness of pain (Anderson, Sheth,
Bencherif, Frost, & Campbell, 2002), although this effect is
rarely observed with short-lasting experimental pain stimuli
(Berna et al., 2018; Eippert et al., 2008; Grevert & Goldstein,
1977). Very recently, studies indicate that social reward pro-
cesses are similarly modulated by opioids in humans. Indeed,
opioid agonist and/or antagonist drugs have been reported to
modulate the perceived attractiveness and motivation to view
faces of beautiful women (Chelnokova et al., 2014), the rela-
tive pleasantness of nude images and frustration at missed
opportunity to view these (Buchel, Miedl, & Sprenger,
2018), visual exploration of faces (Chelnokova et al., 2016),
and perception of faces with emotional expressions (Bershad,
Seiden, & de Wit, 2016; Loseth et al., 2018; Syal et al., 2015;
Wardle, Bershad, & de Wit, 2016).
Overall, these findings are in line with the notion that mu-
opioid receptor stimulation by endogenous and exogenous
opioid peptides causes a shift in valuation along a Bhedonic
gradient,^ ranging from displeasure to pleasure. This shift is
not limited to the "liking" of stimuli. Learning and motivation
typically increase with increased valuation (Berridge,
Robinson, & Aldridge, 2009). Evidence from nonhuman an-
imal studies also shows opioid modulation of learning inde-
pendently of Bliking^ responses (Laurent et al., 2015).
Moreover, microstimulation with opioid peptides has been
shown directly to increase motivation for different reward
types in rodents (Mahler & Berridge, 2012) through distinct
neural mechanisms (Wassum, Ostlund, Maidment, &
Balleine, 2009a).
In rodents, wanting, liking, and reward learning can be
modulated by manipulations of opioid receptors in the ventral
and dorsal striatum, ventral pallidum, and the central nucleus
and basolateral parts of the amygdala (Berridge &
Kringelbach, 2015; Wassum, Cely, Balleine, & Maidment,
2011; Wassum, Cely, Maidment, & Balleine, 2009b;
Wassum, Ostlund, et al., 2009a). Recently, Bhedonic hot-
and coldspots^ involved in sweet taste Bliking^ responses also
were identified in the rat insula and prefrontal cortices (Castro
& Berridge, 2017). Studies using PET imaging and pharma-
cological MRI in humans suggest that opioids may indeed
exert their effects on reward-related behavior through recep-
tors in the orbitofrontal cortex, amygdala, thalamus, insular
cortices, ventral and dorsal striatum, and cingulate cortices
(Hsu et al., 2013; Love, Stohler, & Zubieta, 2009; Murray
et al., 2014; Nummenmaa et al., 2018; Petrovic et al., 2008;
Rabiner et al., 2011). A largemeta-analysis of fMRI activation
associated with subjective value processes showed that the
striatum and ventro-medial prefrontal areas (including the
orbitofrontal cortex) are key to the valuation process, whereas
a different network comprised of the anterior insula,
dorsomedial prefrontal cortex, dorsal and posterior striatum,
and thalamus may be recruited in response to arousal or sa-
lience during valuation (Bartra, McGuire, & Kable, 2013).
Recently, rodent researchers have argued convincingly for
opioid involvement in choice behaviors beyond the regulation
of reinforcement and aversion (Laurent et al., 2015). Indeed,
the widespread distribution of opioid receptors throughout the
human brain is consistent with a wider role of this
neuromodulator for cognition and behavior (Figures 1 and 2).
Opioid activation and inhibition also affects other neurotrans-
mitter systems important for cognition, such as dopamine and
norepinephrine (Chaijale et al., 2013; Fields &Margolis, 2015;
Valentino & Van Bockstaele, 2015)
Opioid regulation of cognitive control
and decision making?
By altering motivational processing and/or learning, opioid
drugs could exert profound effects on cognitive control and
reward-based decisions even after a single drug administra-
tion. Work in rodents indeed shows opioid-induced impair-
ments in some measures of sustained attention and response
inhibition (for an up-to-date review see, Jacobson, Wulf,
Browne, & Lucki, 2018). Despite decades of nonhuman ani-
mal research, much less is known about acute opioid modula-
tion of cognition and decision making in humans. Although a
general assumption has been that opioid drugs will impair
concentration, human drug studies collecting measures of
cognitive control and executive function have typically lacked
a strong theoretical motivation for task inclusion.
One recurrent idea in the human literature is that opioids
might impair concentration by reducing arousal and discom-
fort, whereas this same arousal-reducing property might im-
prove cognitive function when participants are tested in stress-
ful situations (Evans & Witt, 1966). Research from the past
decade has renewed interest in how arousal can influence
cognitive control (Aston-Jones & Cohen, 2005). Some studies
have highlighted the specific effects of aversive arousal, i.e.,
heightened arousal in combination with negative valence
(Saunders & Inzlicht, 2015; van Steenbergen, 2015). In
models that describe affect as a two-dimensional space with
the factors arousal and valence (Russell, 2003), aversive
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arousal can be conceptualized as a diagonal in the quadrant
that combines high levels of arousal with negative valence
(Thayer, 1989; Yik, Russell, & Barrett, 1999). Aversive arous-
al is an integral affective response in many tasks requiring
cognitive control (Inzlicht, Bartholow, & Hirsh, 2015).
Recent accounts have suggested that aversive arousal tunes
goal-directed behavior (Dreisbach & Fischer, 2015; van
Steenbergen, Band, & Hommel, 2009) and can be
counteracted by the induction of incidental positive affect
(van Steenbergen, 2015). Accordingly, it is conceivable that
positive affect induced by an opioid drug might downregulate
aversive arousal, thereby influencing cognitive control. Such
opioid effects would be consistent with emerging work on the
stress-relieving properties of opioids (Valentino & Van
Bockstaele, 2015).
In the present paper, we present a synthesis of current
knowledge of opioid regulation of decision making and the
control of goal-directed behavior in the healthy human brain.
The studies reviewed have used pharmacological manipula-
tions in healthy humans together with decision-making and
cognitive-control tasks. Where possible, we also draw on rel-
evant evidence from PET imaging. Our primary objective is to
gain a better understanding of the mechanisms of acute opioid
modulation of cognitive processes. We also discuss the
Fig. 1 Neural circuits involved in decision making (A) and cognitive
control (B) based onmeta analyses (analysis date 24May 2018), showing
forward inference maps of statistically significant (false discovery rate, p
< 0.01) activations in Neurosynth (Yarkoni, Poldrack, Nichols, Van
Essen, & Wager, 2011). (C) Density of mu-opioid receptor expression
as revealed by [11C]-carfentanil PET (mean nondisplaceable binding
potential (BPND) image of 89 PET scans from healthy volunteers; cour-
tesy of Dr. Lauri Nummenmaa). The circuits involved in decision making
and cognitive control show particular high density of mu-opioid receptors
in the limbic system (including thalamus, basal ganglia, and cingulate
cortex) and a moderate density of mu-opioid receptors in cortical regions,
such as insular and lateral-prefrontal cortex. Note that mu-opioid recep-
tors regulate many functions. As shown above, receptors are expressed
throughout the brain, including in regions less commonly associated with
cognition, such as the midbrain (periaqueductal gray), hypothalamus, and
cerebellum. These maps and their conjunctions are available at
Neurovault (Gorgolewski et al., 2015): https://neurovault.org/
collections/4841/
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possible role of the mu-opioid system in indirect modulation
of decision-making and cognitive control via changes in af-
fective states (Braver et al., 2014; Chiew & Braver, 2011;
Dreisbach & Goschke, 2004; Isen & Means, 1983;
Notebaert & Braem, 2016; van Steenbergen, 2015; Vinckier,
Rigoux, Oudiette, & Pessiglione, 2018) and stress (Shields,
Sazma, & Yonelinas, 2016). After a description of the
methods used for our literature review, we will briefly sum-
marize the main results of the reviewed studies for the do-
mains of decision making and cognitive control. This is
followed by an integrative discussion of the reviewed litera-
ture in which we put forward a framework that aims to capture
the reviewed findings and generate testable hypotheses for
future research. Specifically, we propose that opioids influ-
ence decision making and cognitive control by increasing
the subjective value of reward and reducing aversive arousal.
Other avenues for future research are highlighted before we
present some general conclusions.
Literature inclusion
To synthesize the available evidence for acute opioid drug
effects on cognition in healthy human volunteers, we searched
for studies combining opioid agonist and antagonist drugs
with experimental paradigms to investigate decision making,
impulsivity, executive functioning, attention, inhibition, and
effort.We used Pubmed, Scopus and Google Scholar to search
for relevant literature, using a combination of the keyword
"opioid" or drug names, such as naltrexone, naloxone,
remifentanil, buprenorphine, oxycodone, and morphine and
the particular cognitive function (e.g. attention, impulsivity,
decision-making). In addition, we included relevant articles
cited in recent papers or in earlier reviews by Zacny (1995)
and Ersek et al. (2004). Studies were included in this
semisystematic review if they were published as an article in
a peer-reviewed scientific journal, had tested healthy human
volunteers, included a pharmacological manipulation with an
Fig. 2 Left panel: Drugs can affect the opioid system via different
receptor subtypes. The opioid system is made up of four different
opioid receptor types, the mu-, delta, kappa-, and the nociceptin
receptors (Corbett, 2009). Several types of endogenous ligands, such as
endorphins, enkephalins, dynorphins, endomorphins, and nociceptin ac-
tivate these (Calo, Guerrini, Rizzi, Salvadori, & Regoli, 2000; Fichna,
Janecka, Costentin, & Do Rego, 2007). Drugs, such as morphine and
heroin, are considered mu-opioid agonists, i.e., they act primarily on the
mu-opioid receptor (Pasternak, 2001). The drugs that block endogenous
opioid signaling (antagonists, such as naloxone or naltrexone) in humans
typically inhibit activity at both mu- and kappa-receptors. To date, the
mechanism of action of the mu-opioid receptor is best understood. Both
the analgesic and the euphoric effects of opioid drugs are thought to be
mediated by this receptor type (Fields & Margolis, 2015). Although mu-
opioid receptors are widely distributed in the brain (and in other parts of
the body as well), they are in particular highly expressed in limbic brain
areas, such as the basal ganglia, thalamus, and anterior cingulate. They
also are expressed to a moderate extent in cortical areas, such as lateral
prefrontal and insular regions (Henriksen &Willoch, 2008). Right panel:
Mu-opioid receptors are activated by a large number of different drugs,
and they are commonly compared in terms of their efficacy to relieve pain
at a particular dose and administration method. Opioid drugs are often
given as pills (per oral; PO) but also intravenously (IV), transnasally
(TN), subcutaneously (SC), and intramuscularly (IM). We have calculat-
ed a rough estimate of Bmorphine equivalence^ on the basis of available
evidence of analgesic effects. This conversion was primarily based on the
values provided in earlier work (Knotkova, Fine, & Portenoy, 2009;
Zacny, 1995). It is important to emphasize that dosages with similar
analgesic properties can have different effects on cognitive function,
and a simple conversion does not capture the different pharmacokinetics
of different drugs. To emphasize that the conversion is coarse for the
present purposes, we do not report the exact equianalgesic doses of mor-
phine. Instead, we have categorized the dose as a low, medium, or high
dose, using 4 mg and 7 mg IVof morphine as the minimal cutoff values
for the medium and high dose, respectively. As for the opioid antagonists,
these were categorized on the basis of available PET evidence about the
proportion of mu-opioid receptors blocked by a given drug dose
(Mayberg & Frost, 1990). Doses covering 90-100% of receptors are con-
sidered full antagonists (Weerts et al., 2013). Where doses administered
were much higher or lower than this range, this is specified in the text. In
addition to drugs acting primarily as agonists or antagonist to opioid
receptors, the literature also contains several reports from Bmixed
agonists,^ i.e., drugs that act simultaneously as agonists and antagonists
at different opioid receptors (Jacob, Michaud, & Tremblay, 1979). This
category also covers drugs that act as partial agonists and antagonists,
such as buprenorphine, which binds strongly to mu-opioid receptors, but
causes less activation of the receptor than the endogenous ligand.
Buprenorphine is also a kappa-opioid antagonist. These drugs were also
categorized on the basis of their analgesic effects at the doses used in the
literature. Figures were produced with graphics from Servier Medical Art
(smart.servier.com) under Creative Commons BY 3.0 license.
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opioid agonist and/or antagonist drug, and included one or
more paradigms related to the domains of decision making
or cognitive control. Both behavioral results and/or neural
effects using EEG or fMRI were included in the review. For
reasons of clarity and feasibility, papers published before 1957
and studies that measured the relevant drug effects during pain
or in combination with another drug were not considered.
Beyond these limitations, we strived to include all relevant
studies rather than reviewing a subset. Accordingly, we con-
sider our approach a semisystematic review, in the sense that
we did not knowingly exclude evidence contrary to (or con-
sistent with) our own opinions about the topic at hand. To
compare the different drugs and their doses, we calculated a
rough estimate of Bmorphine equivalence^ on the basis of
available evidence of analgesic effects (Figure 2).
A quantitative meta-analysis of effects in the reviewed lit-
erature was not possible due to 1) variable drug types, doses,
and administration methods used across studies, 2) variable
tasks and outcome measures reported, and 3) the failure to
report means and variance information for relevant outcomes
in much of the (earlier) literature. Note that this literature has
typically been statistically underpowered, and for topics
where both null and positive effects are reported, we give
relatively less weight to null findings identified using
frequentist statistics only.
Review of studies on decision-making
Reward-based decision-making
Only a handful of studies have investigated the behavioral,
neural, and psychophysiological responses to reward-based
decisions following pharmacological manipulation of the opi-
oid system in healthy humans. In general, these studies are
consistent with the available evidence on opioid modulation
of rewards presented outside of a decision context. Petrovic
and colleagues (Petrovic et al., 2008) used opioid blockade
(10 mg IV naloxone, placebo-controlled) to assess the role of
endogenous opioids during a gambling task with rewards and
losses in 15 healthy men (within-subject). Following nalox-
one, monetary losses were rated as more aversive and the
opioid blockade increased activation in regions such as the
ACC and anterior insula. Pleasantness ratings of wins were
unaltered by opioid blockade, which nevertheless decreased
ACC responses to these rewards. Another study reported no
clear effects of opioid blockade (50 mg naltrexone) on BOLD
responses to monetary wins and losses (Monetary Incentive
Delay task) in 35 healthy participants (Nestor et al., 2017).
Very recently, a third fMRI study using naloxone and an in-
centive delay task with monetary gain and erotic images in 21
healthy men (within-subject) found that compared with place-
bo, opioid blockade decreased the relative pleasantness of
both types of high-value rewards but with a significantly
stronger effect on erotic images (Buchel et al., 2018). The
authors observed reduced BOLD response to erotic images
in bilateral striatum, orbitofrontal cortex, the amygdalae, pre-
frontal cortex, and hypothalamus but no reduced response to
(symbolic) receipt of monetary gains. During the anticipation
phase, a small reduction in medial prefrontal cortex and right
lateral orbitofrontal cortex activity was observed during cues
signaling potential monetary gains (but not erotic images).
Thus, initial evidence of opioid modulation of pleasantness
and fMRI responses to rewarded decisions in humans is mod-
est but consistent with the evidence that opioids promote the
pleasantness of rewards received outside of a decision context
(Chelnokova et al., 2014, 2016; Drewnowski et al., 1992;
Eikemo et al., 2016; Murray et al., 2014; Price et al., 2016;
Yeomans, 1995; Yeomans & Gray, 2002). Whether opioid
agonist drugs increase the liking of choice outcomes in
humans remains to be seen.
Reward learning and motivation in decision making
What about opioid modulation of reward learning and moti-
vation in humans? Studies using measures of motivation and
learning have shown more consistent opioid modulations than
those on reward responses. Using a Pavlovian instrumental
transfer (PIT) task with chocolate reinforcement, Weber
et al. (2016) found a significant reduction in the difference
between button presses for rewarded and unrewarded stimuli
following 50 mg naltrexone (n = 40) compared with placebo
(n = 40), indicating reduced motivation to exert effort for
rewards after opioid blockade. Eikemo et al. (2017) tested
the effects of 50 mg of naltrexone, 10 mg of morphine, and
placebo on rewarded choice in healthy men (n = 30, within-
subjects). Using a drift diffusion model, they found that mu-
opioid agonism enhanced and blockade decreased, processing
efficiency in the reward task, which they interpreted as a mea-
sure of motivation to obtain reward. Morphine also increased
the bias towards the high-value response option (associated
with high reward probability). Using opioid blockade (50 mg
of naltrexone, n = 21) and placebo (n = 20) before a slot-
machine task and roulette task, Porchet et al. (2013) found
that naltrexone moderately attenuated the motivational ratings
after near-misses compared with placebo. However, contrary
to the above reviewed findings, participants under opioid
blockade also exhibited signs of increased reward sensitivity
(a larger change in the skin conductance response to wins and
higher confidence following winning-streaks). Finally, a study
of opioid effects on financial decisions (trading game) sug-
gested that opioid blockade (naltrexone 50 mg, n = 62) de-
creases reinforcement learning compared with placebo (n =
116) in healthy participants (Efremidze, Sarraf, Miotto, &
Zak, 2017).
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In summary, the available evidence provides some support
for involvement of the endogenous opioid system in value-
based decisionmaking, suggesting that blocking opioid recep-
tors may reduce, and stimulating receptors may enhance, the
motivational value of and learning about high-value stimuli
and choices for these options. However, pharmacological
studies in healthy humans are still scarce, and results are not
homogenous. So far, the opioid effects on value-based deci-
sion making appear broadly consistent with the extensive ev-
idence from rodent research (Berridge & Kringelbach, 2015;
Laurent et al., 2015; Lutz & Kieffer, 2013), but more research
into this area in humans is needed.
Impulsive choices
Impulsivity is a broad construct related to impulsive choice (as
measured by probability discounting, gambling tasks, and de-
lay discounting) and impulsive action (e.g., failure to inhibit
prepotent responses, see Inhibition and Effort). Correlations
between trait impulsivity and performance on tasks measuring
impulsive choice or action are low, as are correlations of per-
formance between these tasks. Nevertheless, trait impulsivity
has been related to opioid receptor binding in a PET study.
Specifically, NEO Personality Inventory (Costa & McCrae,
1992) measures related to lack of control over cravings or
desires, correlated with receptor-binding potential in medial
frontal cortex, nucleus accumbens/ventral pallidum, and the
right amygdala in 19 young males (Love et al., 2009).
A handful of opioid drug studies have investigated impul-
sive choices using delay discounting tasks where subjects
choose between smaller immediate rewards or larger delayed
rewards. Two initial studies reported no significant effect of
naltrexone (50 mg PO) on impulsive choice ratio in nine
(Mitchell, Tavares, Fields, D’Esposito, & Boettiger, 2007)
and ten healthy controls (Boettiger, Kelley, Mitchell,
D’Esposito, & Fields, 2009). In a larger study by Weber
et al. (2016), a trend towards reduced impulsive choice was
reported in 40 healthy people receiving naltrexone (50 mg)
compared with a placebo group of the same size. Few studies
report effects of opioid agonism on impulsivity measures in
healthy humans. In Zacny and de Wit (2009), a battery of five
tasks measuring aspects of choice and motor impulsivity was
administered following three separate doses of oxycodone (5,
10, or 20 mg PO) compared with placebo (within-subject; n =
12). They did not find any significant effect on any of the
tasks, including delay discounting, even at the higher oxyco-
done doses where participants reported feeling the drug ef-
fects. Furthermore, Eikemo et al. (2017) found no credible
effects of either 50 mg of naltrexone or 10 mg of morphine
on reward-related impulsivity as measured by speed-accuracy
trade-off in a probabilistic reward task.
Together, these results indicate that blocking the majority
(>90%) of the μ-opioid receptors in the brain using 50 mg of
naltrexone (Weerts et al., 2013) does not cause a large reduc-
tion in measures of impulsive reward choices in healthy
humans. Rodent work similarly indicates limited or no effects
of opioid blockade on tests of impulsive behavior (Kieres
et al., 2004; Pattij, Schetters, Janssen, Wiskerke, &
Schoffelmeer, 2009). For opioid agonism, the preliminary ev-
idence in humans is at odds with rodent findings that acute
opioid administration increases impulsivity.
Review of studies on cognitive control
Neuropsychological tests of executive functions
The nonhuman animal literature yields minimal information
about opioid modulation of executive function. These func-
tions are typically impaired in opioid dependence, but this
impairment could be related to other factors and mechanisms
than opioid receptor functioning. Indeed, working memory
training was shown to increase future orientation and decrease
delay discounting in opioid-dependent individuals (Bickel, Yi,
Landes, Hill, & Baxter, 2011). While the little evidence avail-
able from opioid antagonist studies do not suggest a central
role of the endogenous opioid system in executive function,
studies employing acute doses of opioid agonists do report
modulation of executive functions.
Most consistent evidence for an impact of opioid drugs on
executive function comes from studies implementing the digit
symbol substitution task (DSST, also known as the coding
task), which requires participants to substitute symbols and
digits using a particular key. The DSST is the most commonly
included task in opioid administration studies. A speeded sub-
test of the Wechsler Adult Intelligence Scale, it is designed to
measure functions related to Bprocessing speed^ (Wechsler,
2014). However, recent work has shown that the DSST task
does not asses basic psychomotor speed, but instead reflects a
mixture of executive functioning processes including inhibi-
tion, shifting, and updating (Knowles et al., 2015).
An early study reported that a low dose of the opioid ago-
nist codeine impairs coding performance in medical troops
tested at 2,000 feet (610 meters) altitude but improved perfor-
mance when they performed this test at 15,000 feet (4,572
meters) elevation (Evans &Witt, 1966). Few subsequent stud-
ies have assessed context-sensitive effects of opioids on cog-
nition. Instead most studies have simply included DSST per-
formance as part of a cognitive test battery in a standard psy-
chopharmacological protocol with no systematic manipula-
tion of context. More than 30 such studies have investigated
the effects of various types of opioid agonists. The majority of
these studies have observed coding impairments (Table 1).
Two studies using opioid antagonists reported no effect on
coding performance (File & Silverstone, 1981; Zacny,
Coalson, Lichtor, Yajnik, & Thapar, 1994a). As Figure 3 (left
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panel) shows, most performance impairments have been re-
ported in studies using high doses of opioid agonists only,
although some studies have observed performance decre-
ments at medium doses (e.g., hydrocodone, oxycodone, and
partial agonists). This suggests that the effect of opioid ago-
nists on coding performance might be dose-related, even
though a clear link between plasma concentrations and
DSST impairments is currently lacking (Strand, Arnestad,
Fjeld, & Mørland, 2017).
Another commonly investigated function in the context of
opioid drugs is logical reasoning. Effects of opioid agonists on
a logical reasoning task were first reported by Evans and
Smith (1964) who observed that a low dose of morphine in
four participants improved performance on a test assessing
logical judgements compared with four placebo-treated peo-
ple. However, the majority of subsequent studies in larger
samples have failed to replicate this effect with low opioid
drug doses (Table 2), although some impairments in logical
reasoning have been observed with medium and high doses of
full and mixed agonists (Figure 3, right panel). We are not
aware of studies that have reported the effects of opioid an-
tagonists on logical reasoning.
Working memory is a central aspect of executive function-
ing that is well known to be modulated by catecholamine
systems that directly modulate prefrontal brain activity
(Robbins & Arnsten, 2009). Interestingly, across a wide vari-
ety of doses and drugs in 16 studies, opioid agonists and
antagonists typically do not affect working memory perfor-
mance (Table 3). Three studies did observe effects on working
memory (Ghoneim, Mewaldt, & Thatcher, 1975; Martín del
Campo, McMurray, Besser, & Grossman, 1992; Székely,
Török, Karczag, Tolna, & Till, 1986) but showed findings in
opposite directions and had small study samples (8 or 10
males per study).
The handful of studies assessing effects of opioid agonist
and antagonist treatment on mathematical skills are summa-
rized in Table 4. The available evidence suggests that high
doses of opioids drugs might impair several aspects of math-
ematical skills, including the speed at which participants com-
plete oral and written addition tasks as reported by Smith and
colleagues (Smith, Semke, & Beecher, 1962). However, other
studies using low or moderate doses of opioid agonists failed
to observe effects (Cleeland et al., 1996; Kornetsky,
Humphries, & Evarts, 1957; Cherrier, Amory, Ersek, Risler,
& Shen, 2009). Opioid blockade has not been shown to mod-
ulate arithmetic skills (Martín del Campo et al., 1992).
Cognitive flexibility, another key aspect of executive func-
tion, is rarely investigated in the context of opioid drug stud-
ies. In an early study, Primac et al. (1957) did not find an effect
of a low dose of the opioid agonistMeperidine administered to
ten participants on the Wisconsin Card Sorting Test (WCST).
More recently, Quednow and colleagues (Quednow, Csomor,
Chmiel, Beck, & Vollenweider, 2008) using a low dose of
10 mg PO of morphine in 18 males did not observe effects
on the Stockings of Cambridge tasks or extradimensional set
switching. However, their low dose of morphine did reduce
the error rate on intradimensional set shifts, suggesting that
low doses of opioids might help to improve the application of
a task rule within the same perceptual dimension.
The effects of opioid drugs on neuropsychological tests of
executive function have most often been investigated in the
domains of coding, logical reasoning, and working memory.
While a large proportion of studies did observe opioid agonist-
induced impairments in coding and logical reasoning, there
are no consistent effects of opioid drugs on working memory.
Attention
In an early study, Arnsten et al. (1983, 1984) hypothesized
that blocking endogenous opioid activity might improve the
selectivity of attention. Using a small dose (2 mg IV) of nal-
oxone in an EEG study of ten male participants, they indeed
observed that naloxone increased a late frontal event-related
potential component, which is thought to reflect attention to
auditory stimuli. Findings were consistent with their prior
findings in animals (Arnsten et al., 1981) and were suggested
to be driven by interactions with the locus-coeruleus-
norepinephrine system. However, a more recent study testing
four females and nine males using a higher dose of the opioid
antagonist naltrexone (50 mg PO) to block >90% of mu-
opioid receptors observed an effect in a direction opposite to
the findings by Arnsten and colleagues (Jääskeläinen et al.,
1998). These authors speculated that the observed impairment
in selectivity of attention in their study might be due to nausea
induced by naltrexone in their participants. Thus, a full opioid
blockade (>90%) appears to cause the opposite attentional
effect of weak opioid blockade. Other studies using high doses
of opioid agonists did not observe clear impairments in divid-
ed attention task performance (Saarialho-Kere, 1988;
Saarialho-Kere, Mattila, & Seppälä, 1989; for procedural de-
tails of these studies see Table 1). These null-effects were
supported by the finding that a low dose of infused
remifentanil (n = 14, within-subjects) impaired attention in a
letter detection task only when participants expected that the
drug would be administered but not when they did not expect
the drug (open vs. hidden administration; Atlas, Wielgosz,
Whittington, & Wager, 2014).
The ability to regulate sensory input by filtering out irrele-
vant stimuli (to prevent sensory overflow) can also be en-
hanced by opioid agonists, as suggested by a study where a
low dose of morphine (10 mg PO) in 18 males enhanced
modulation of the startle reflex to a noise burst following a
prestimulus, a phenomenon called prepulse inhibition
(Quednow et al., 2008). At first sight, these findings seem
difficult to reconcile with the findings reported by Arnsten
et al. (1983, 1984). As we will discuss in more detail later,
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one possibility is that the task by Quednow et al. (2008) in-
volved increased levels of distress because of the loud audito-
ry noise involved in the task. Opioids might help to downreg-
ulate stress responses under such conditions, perhaps improv-
ing sensorimotor gating relative to placebo. However, as
reviewed elsewhere (Jacobson et al., 2018), effects of opioid
drugs on prepulse inhibition in rodents are mixed, showing
that additional systematic research is needed.
Inhibition and effort
The effects of blocking opioid receptors on response inhibi-
tion were investigated by Martin del Campo et al. (1992)
using the Stroop task and more recently in a Stroop-like
prime-probe task by van Steenbergen et al. (2017). The first
study used a cumulative infusion of naloxone in 8 males and
the other administered 50 mg naltrexone PO versus placebo in
two groups of 26 female participants. Both studies revealed
that overall Stroop performance was not affected by the phar-
macological manipulation. Likewise, no significant effects
were reported by the earlier described study by Zacny and
de Wit on impulsive action, which investigated the effect of
5, 10, and 20 mg PO of oxycodone in six females and six
males participants on stop-signal performance and go/no-go
performance (Zacny & de Wit, 2009). The absence of clear
findings on overall measures of response inhibition resonates
with rodent studies that often find no or mixed effects of
opioid manipulations on premature responding (Jacobson
et al., 2018).
The study by van Steenbergen and colleagues also ana-
lyzed post-error and post-conflict adjustments in behavioral
performance (2017), which are thought to reflect short-term
adaptive increases in cognitive control triggered by aversive
arousal integral to the task at hand (Botvinick, Braver, Barch,
Carter, & Cohen, 2001; Dreisbach & Fischer, 2012; Inzlicht
et al., 2015; van Steenbergen, 2015). Naltrexonewas observed
to increase reaction time slowing after participants made an
error. This finding suggests that the aversive arousal associat-
ed with conflict and errors can be increased when endogenous
opioid activity is blocked, which improves short-term adap-
tive cognitive control. On the other hand, chronic stress and
depression is associated with hyperactive neural error moni-
toring, impairing post-error accuracy (Pizzagalli, 2011).
Recent work in rodents has shown that a kappa-specific an-
tagonist can ameliorate stress-induced post-error impairments
(Beard et al., 2015). This illustrates that modulation of aver-
sive arousal is not restricted to mu-opioid receptors (Valentino
& Van Bockstaele, 2015).
Two studies have investigated the effect of the opioid sys-
tem on perceived task difficulty and required effort. Grossman
et al. (1984) reported a study that tested the effect of an opioid
blockade (12.2 mg IV of naloxone) in six male participants
performing a physical exercise task. This opioid antagonist
increased the perceived difficulty of the task. Two further
studies reported that opioid blockade abolished exercise-
induced mood improvements (Allen & Coen, 1987; Daniel,
Martin, & Carter, 1992), conceivably through increased per-
ceived difficulty. Interestingly, a more recent study has ob-
served that the opioid agonist oxycodone (10 mg PO) admin-
istered to 18 participants did not affect driving performance,
whereas they did report increases in required effort while
performing the task (Verster, Veldhuijzen, & Volkerts, 2006).
This finding points to the possibility that compensatory effort
(Hockey, 1997) might mask opioid-related impairment in per-
formance on cognitive control tasks.
Integrative discussion of the reviewed literature
What can be learned from the budding literature on human
opioid regulation of cognition and decision making? In light
of the moderate to high density of mu-opioid receptors in the
brain circuits involved in decision making and cognitive con-
trol (Figure 1), endogenous or drug modulation of mu-opioid
receptors could exert direct modulatory effects on these
Fig. 3 The number of times opioid agonist drug has shown a significant
impairment on coding task (DSST) performance and logical reasoning for
all type of drugs used in the studies (antagonist drug effects not included,
see details in Tables 1 and 2). Dose refers to the minimal dose needed to
produce a significant effect; if no effect was observed, we used the max-
imum dose used in the study.
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processes. Nevertheless, considering all reviewed evidence
together, one striking observation is the abundance of phar-
macological studies observing null effects. This is true in par-
ticular for the delay-discounting tasks, working memory task
and overall measures of planning, switching, and inhibition.
However, the majority of these studies have used only small to
moderate sample sizes, which usually are only adequately
powered to observe medium to high effect sizes.
Considering that typical effects sizes in the field of psycholo-
gy and affective neuroscience are small to moderate (Lakens
& Evers, 2014; Poldrack et al., 2017), the majority of the
published studies were underpowered to detect such effects.
One conclusion that can be drawn is thus that new research in
this area must take measures to improve statistical power. In
the meantime, we advise caution in the interpretation of these
null effects, in particular if the study used low or moderate
doses of opioid agonists only.
Null effects reported after full (>90%) blockade of mu-
opioid receptors are an intermediate case, since valuable in-
formation can indeed be gleaned by observing behaviors un-
altered or only partly diminished when opioid signaling is
blocked. For instance, it is striking that healthy people display
comparable working memory capacity and cognitive flexibil-
ity after treatment with opioid agonists, antagonists, and pla-
cebo. Similarly, although several studies report reduced re-
ward pleasantness after naloxone or naltrexone, healthy
humans consistently report substantial enjoyment of rewards
when mu-opioid receptors are fully blocked. The clearest pat-
terns indicating opioid modulation of performance emerged
for value-based learning and decision-making tasks, the
DSST, and the logical reasoning task. We will elaborate on
these results below and highlight potential neural
mechanisms.
Reward-based decision-making
The reviewed evidence from studies of reward-based deci-
sion-making in humans is largely consistent with opioid reg-
ulation of reward motivation, as measured by effort invested
to obtain relatively high-value rewards (Chelnokova et al.,
2014; Eikemo et al., 2017; Weber et al., 2016). Extensive
evidence from non-human animals indicates a parallel mech-
anism (Mahler & Berridge, 2012; S. Peciña & Berridge,
2013). We speculate that the rewarding effects of exerting
physical effort during exercise (Allen & Coen, 1987; Daniel
et al., 1992; Grossman et al., 1984; Hiura et al., 2017;
Saanijoki et al., 2018) or cognitive effort (Inzlicht, Shenhav,
& Olivola, 2018) may be mediated by the opioid system. Note
that the existing literature in healthy humans does not allow us
to disentangle the decision processes involved in weighing
costs, such as effort expenditure, against gains, such as social,
monetary, or taste rewards.Ta
bl
e
2
(c
on
tin
ue
d)
R
ef
er
en
ce
S
am
pl
e
D
ru
g
ty
pe
D
ru
g
R
ou
te
D
os
e
M
ax
do
se
1
E
ff
ec
t2
E
ff
ec
t
do
se
3
A
go
ni
st
O
xy
co
do
ne
PO
5
m
g
O
xy
co
do
ne
/3
25
m
g
A
ce
ta
m
in
op
he
n,
10
m
g
O
xy
co
do
ne
/6
50
m
g
A
ce
ta
m
in
op
he
n
m
ed
↓
m
ed
Z
ac
ny
&
L
ic
ht
or
,2
00
8
10
F/
10
M
A
go
ni
st
M
or
ph
in
e
PO
30
,6
0
m
g
hi
gh
↓
hi
gh
A
go
ni
st
O
xy
co
do
ne
P
O
10
,2
0
m
g
hi
gh
↓
hi
gh
Z
ac
ny
&
G
ut
ie
rr
ez
,2
00
9
10
F/
10
M
A
go
ni
st
H
yd
ro
co
do
ne
PO
15
m
g
H
yd
ro
co
do
ne
/4
87
m
g
A
ce
ta
m
in
op
he
n,
30
m
g
H
yd
ro
co
do
ne
/9
75
m
g
A
ce
ta
m
in
op
he
n
hi
gh
↓
m
ed
A
go
ni
st
O
xy
co
do
ne
PO
10
m
g
O
xy
co
do
ne
/4
87
m
g
A
ce
ta
m
in
op
he
n,
20
m
g
O
xy
co
do
ne
/9
75
m
g
A
ce
ta
m
in
op
he
n
hi
gh
↓
m
ed
Z
ac
ny
&
G
ut
ie
rr
ez
,2
01
1
6F
/8
M
A
go
ni
st
O
xy
co
do
ne
PO
10
m
g
m
ed
...
_
F
=
fe
m
al
e;
M
=
m
al
e
pa
rt
ic
ip
an
ts
.S
tu
di
es
us
ed
w
ith
in
-s
ub
je
ct
de
si
gn
s
un
le
ss
ot
he
rw
is
e
no
te
d.
1
E
st
im
at
ed
do
se
fo
ra
go
ni
st
s
ba
se
d
on
m
or
ph
in
e
eq
ui
va
le
nt
of
th
e
m
ax
im
um
do
se
of
in
th
e
re
sp
ec
tiv
e
st
ud
y.
F
or
an
ta
go
ni
st
dr
ug
s,
th
e
es
tim
at
ed
do
se
is
pr
ec
ed
ed
by
a
m
in
us
.S
ee
ca
pt
io
n
of
Fi
gu
re
2
fo
rm
or
e
de
ta
ils
.
2
A
rr
ow
in
di
ca
te
s
si
gn
if
ic
an
tly
im
pr
ov
ed
(↑
)
,i
m
pa
ir
ed
(↓
),
m
ix
ed
ef
fe
ct
s
(↕
)
or
nu
ll-
ef
fe
ct
s
(…
)
on
pe
rf
or
m
an
ce
re
la
tiv
e
to
a
pl
ac
eb
o
co
nt
ro
lc
on
di
tio
n.
3
M
in
im
um
es
tim
at
ed
do
se
at
w
hi
ch
th
e
in
di
ca
te
d
ef
fe
ct
is
si
gn
if
ic
an
tly
di
ff
er
en
tf
ro
m
pl
ac
eb
o.
446 Cogn Affect Behav Neurosci (2019) 19:435–458
Ta
bl
e
3
Ph
ar
m
ac
ol
og
ic
al
st
ud
ie
s
re
po
rt
in
g
ef
fe
ct
on
w
or
ki
ng
m
em
or
y
R
ef
er
en
ce
S
am
pl
e
D
ru
g
ty
pe
D
ru
g
R
ou
te
D
os
e
M
ax
do
se
1
E
ff
ec
t2
E
ff
ec
t
do
se
3
E
va
ns
&
Sm
ith
,1
96
4
4F
/M
ve
rs
us
4F
/M
A
go
ni
st
M
or
ph
in
e
PO
16
m
g
lo
w
...
_
G
ho
ne
im
,M
ew
al
dt
,&
T
ha
tc
he
r,
19
75
10
M
A
go
ni
st
Fe
nt
an
yl
IV
0.
1,
0.
2
m
g
hi
gh
↓
hi
gh
A
go
ni
st
Fe
nt
an
yl
IV
0.
1,
0.
2
m
g
hi
gh
...
_
V
ol
av
ka
,D
or
nb
us
h,
M
al
ly
a,
&
C
ho
,1
97
9
26
M
A
nt
ag
on
is
t
N
al
ox
on
e
IV
10
,2
0
m
g
-m
ed
...
_
Fi
le
&
Si
lv
er
st
on
e,
19
81
6F
/6
M
A
nt
ag
on
is
t
N
al
ox
on
e
IV
0.
8,
1.
6
m
g
-l
ow
...
_
C
oh
en
,M
ur
ph
y,
C
oh
en
,W
ei
ng
ar
tn
er
,&
Pi
ck
ar
,
19
83
3F
/4
M
A
nt
ag
on
is
t
N
al
ox
on
e
IV
21
,7
0,
14
0
m
g
-h
ig
h
...
_
Sz
ék
el
y,
T
ör
ök
,K
ar
cz
ag
,T
ol
na
,&
T
ill
,1
98
6
8M
A
go
ni
st
D
ih
yd
ro
co
de
in
e
SC
20
m
g
lo
w
↑
lo
w
Sa
ar
ia
lh
o-
K
er
e,
M
at
til
a,
&
Se
pp
äl
ä,
19
88
11
F/
M
M
ix
ed
ag
on
is
t
Pe
nt
az
oc
in
e
IM
30
m
g
m
ed
...
_
M
ac
D
on
al
d,
G
ou
gh
,N
ic
ol
l,
&
D
ow
,1
98
9
12
M
M
ix
ed
ag
on
is
t
B
up
re
no
rp
hi
ne
IM
0.
3
m
g
hi
gh
...
_
M
ar
tín
de
lC
am
po
,M
cM
ur
ra
y,
B
es
se
r,
&
G
ro
ss
m
an
,1
99
2
8M
A
nt
ag
on
is
t
N
al
ox
on
e
IV
C
um
ul
at
iv
e
in
fu
si
on
:1
0-
m
g
bo
lu
s
of
N
al
ox
on
e
w
as
gi
ve
n
as
a
ra
pi
d
bo
lu
s,
fo
llo
w
ed
by
an
in
fu
si
on
of
7
m
g/
hr
fo
r
12
hr
-m
ed
↓
-m
ed
H
an
ks
,O
’N
ei
ll,
Si
m
ps
on
,W
es
ne
s,
&
A
,1
99
5
4F
/8
M
A
go
ni
st
M
or
ph
in
e
PO
10
,1
5
m
g
lo
w
...
_
Z
ac
ny
,L
ic
ht
or
,K
la
ft
a,
A
le
ss
i,
&
A
pf
el
ba
um
,
19
96
a
3F
/7
M
A
go
ni
st
C
od
ei
ne
PO
60
m
g
C
od
ei
ne
/6
00
m
g
A
ce
ta
m
in
op
he
n
lo
w
...
_
M
ix
ed
ag
on
is
t
B
ut
or
ph
an
ol
T
N
1,
2
m
g
hi
gh
...
_
B
la
ck
,H
ill
,&
Z
ac
ny
,1
99
9
2F
/8
M
A
go
ni
st
A
lf
en
ta
ni
l
IV
16
,3
2,
64
ng
/m
l
hi
gh
...
_
A
go
ni
st
R
em
if
en
ta
ni
l
IV
C
on
tin
uo
us
in
fu
si
on
:0
.7
5,
1.
5,
3
ng
/m
l
hi
gh
...
_
Z
ac
ny
&
G
ol
dm
an
,2
00
4
9F
/9
M
A
go
ni
st
M
or
ph
in
e
PO
40
m
g
m
ed
...
_
A
go
ni
st
Pr
op
ox
yp
he
ne
na
ps
yl
at
e
PO
50
,1
00
,2
00
m
g
m
ed
...
_
V
er
st
er
,V
el
dh
ui
jz
en
,&
V
ol
ke
rt
s,
20
06
12
F/
6M
A
go
ni
st
O
xy
co
do
ne
PO
5
m
g
O
xy
co
do
ne
/3
25
m
g
A
ce
ta
m
in
op
he
n,
10
m
g
O
xy
co
do
ne
/6
50
m
g
A
ce
ta
m
in
op
he
n
m
ed
...
_
Fr
is
w
el
le
t
al
.,
20
08
9F
/9
M
A
go
ni
st
M
or
ph
in
e
PO
10
m
g
lo
w
...
_
A
go
ni
st
M
or
ph
in
e
PO
10
m
g
lo
w
...
_
A
go
ni
st
O
xy
co
do
ne
PO
5
m
g
lo
w
...
_
A
go
ni
st
O
xy
co
do
ne
PO
5
m
g
lo
w
...
_
Q
ue
dn
ow
,C
so
m
or
,C
hm
ie
l,
B
ec
k,
&
V
ol
le
nw
ei
de
r,
20
08
18
M
A
go
ni
st
M
or
ph
in
e
PO
10
m
g
hi
gh
...
_
F
=
fe
m
al
e;
M
=
m
al
e
pa
rt
ic
ip
an
ts
.S
tu
di
es
us
ed
w
ith
in
-s
ub
je
ct
de
si
gn
s
un
le
ss
ot
he
rw
is
e
no
te
d.
1
E
st
im
at
ed
do
se
fo
ra
go
ni
st
s
ba
se
d
on
m
or
ph
in
e
eq
ui
va
le
nt
of
th
e
m
ax
im
um
do
se
of
in
th
e
re
sp
ec
tiv
e
st
ud
y.
F
or
an
ta
go
ni
st
dr
ug
s,
th
e
es
tim
at
ed
do
se
is
pr
ec
ed
ed
by
a
m
in
us
.S
ee
ca
pt
io
n
of
Fi
gu
re
2
fo
rm
or
e
de
ta
ils
.
2
A
rr
ow
in
di
ca
te
s
si
gn
if
ic
an
tly
im
pr
ov
ed
(↑
)
,i
m
pa
ir
ed
(↓
),
m
ix
ed
ef
fe
ct
s
(↕
)
or
nu
ll-
ef
fe
ct
s
(…
)
on
pe
rf
or
m
an
ce
re
la
tiv
e
to
a
pl
ac
eb
o
co
nt
ro
lc
on
di
tio
n.
3
M
in
im
um
es
tim
at
ed
do
se
at
w
hi
ch
th
e
in
di
ca
te
d
ef
fe
ct
is
si
gn
if
ic
an
tly
di
ff
er
en
tf
ro
m
pl
ac
eb
o.
Cogn Affect Behav Neurosci (2019) 19:435–458 447
The current literature also points to a modest opioid mod-
ulation of the rewarding experience (liking) of high-value
stimuli, but so far there is little evidence of a change in the
neural response of winning money in healthy humans. One of
the studies reviewed also points to opioid modulation of
(monetary) reward learning (Efremidze et al., 2017). Overall,
however, findings are in line with the notion that mu-opioid
receptor stimulation by endogenous and exogenous opioid
peptides causes a shift in valuation along a Bhedonic gradient^
ranging from unpleasant to pleasurable. As illustrated in
Figure 4, we suggest that increased enjoyment of and motiva-
tion towards rewarding stimuli could underlie the observed
changes in decision making. Studies in both rodents and
humans indicate that these effects may be most pronounced
for highly salient stimuli, such as high-value rewards.
Notably, these studies consistently show that blocking
more than 90% of mu-opioid receptors does not obliviate the
appreciation of a rewarded choice and only moderately re-
duces the pleasantness of rewards in general. Interestingly,
while there is strong evidence that opioid drugs enhance
food-liking responses in rodents, mu-opioid antagonism di-
rectly into Bhedonic hotspots^ did not suppress such
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Fig. 4 Subjective value as a function of reward and punishment. The gray
line plots a typical value function for reward and punishment according to
prospect theory (Kahneman & Tversky, 1979). Opioid drugs might mod-
ulate decision making by shifting this value function, such that opioid
agonists increase (white line) and opioid antagonists decrease (black line)
subjective value for rewards. Similar modulation specifically of high-
salience stimuli may occur for punishments (dotted lines), although the
available evidence is equivocal and future research is warranted (see
Discussion in main text).
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appetite-independent Bliking^ (Smith & Berridge, 2007;
Wassum et al., 2009b). However, systemic antagonism in ro-
dents has been shown to suppress liking of sweet taste (Parker,
Maier, Rennie, & Crebolder, 1992).
Opioid agonists might similarly attenuate the negative val-
ue of punishments, although the exact nature of this modula-
tion requires extensive future research. For example, there is
some evidence that opioid drugs may modulate large and
small punishments to the same extent (Atlas et al., 2014;
Gospic et al., 2007; Murray et al., 2014; Petrovic et al.,
2008; Price, Harkins, Rafii, & Price, 1986; Schoell et al.,
2010). Moreover, despite the relief opioid drugs can provide
for acute clinical and experimental pain (Wanigasekera et al.,
2012), psychosocial stress (Bershad et al., 2015, 2018), certain
depressive symptoms (Peciña et al., 2018), and feelings of
breathlessness (Hayen et al., 2017), opioid blockade does
not consistently increase the aversiveness of experimental
pain (Anderson et al., 2002; Berna et al., 2018; Eippert
et al., 2008; Grevert & Goldstein, 1977). Clearly, more well-
powered psychopharmacological evidence is needed to under-
stand opioid modulation of reward and punishment processes,
as well as their integration in the human brain.
Cognitive control
With respect to the cognitive control domain, studies showed
the most consistent effects (the highest proportion of signifi-
cant effects) for the coding task (DSST). This is also the task
that has been most frequently included in opioid drug studies.
At moderate and high opioid drug doses, clear impairments on
performance have been observed in many studies using this
task (Figure 3). Although the DSST often is used as a primary
measure of psychomotor skills, recent work using a factor-
analytic approach suggest that performance on the DSST does
not rely on basic psychomotor speed but instead relies on
several executive function processes including working mem-
ory updating, switching, and inhibition (Knowles et al., 2015).
This task might require a delicate coordination and integration
of these different control processes. It could be speculated that
this has rendered the DSST, and to a lesser extent logical
reasoning, the most sensitive measures of cognitive control
impairment. On the other hand, no evidence exists that
blocking opioids enhances coding or logical reasoning perfor-
mance in healthy people, which speaks against involvement of
the endogenous opioid system as a key mechanism in execu-
tive functions. Indeed, other tasks in the cognitive domain,
which are typically constructed to tap into a single subtype
of control processes, were not associated with strong effects of
opioid drugs or blockade. Combined, these results indicate
that the effects of opioid drugs at moderate to high doses will
be particularly strong for tasks which require the orchestration
of multiple cognitive control functions relying on different
regions in frontoparietal brain circuits. However, given the
sparse data on cognitive measures other than DSST and logi-
cal reasoning, future research is warranted before firm conclu-
sions can be drawn regarding the effects of opioids on these
measures.
Working hypothesis: Enhanced cognitive
performance after opioid-reduced aversive arousal?
Some evidence suggests that opioid agonist administration
relative to placebo can also improve rather than impair perfor-
mance. This was for example observed for logical reasoning
and DSST performance in early studies by Evans and col-
leagues (Evans & Smith, 1964; Evans & Witt, 1966) as well
as in more recent work on intradimensional set shifting and
attention (Quednow et al., 2008). These studies have in com-
mon that they used low doses of morphine (or codeine). One
possible explanation for these findings might be that low
doses of opioid agonists could reduce the aversive arousal
(Thayer, 1989) or distress associated with a task. If the rela-
tionship between aversive arousal and cognitive control fol-
lows an inverted U-shape, as previous work has proposed (van
Steenbergen, Band, & Hommel, 2015), low doses of opioid
agonist drugs might compensate for arousal-induced impair-
ment that occurs in the placebo condition (Figure 5). Opioids
indeed tend to reduce arousal and can cause sedation at high
doses. Even at lower doses, opioid agonists in humans and
some other species reduce pupil size (miosis) (Lee & Wang,
1975; Murray, Adler, & Korczyn, 1983). In addition, opioid
antagonism increases cortisol responses, and this is thought to
reflect blockade of a tonic endogenous opioid inhibition of
cortisol in humans (Lovallo et al., 2015).
Fig. 5 U-shaped relationship between aversive arousal and cognitive
control. Opioids agonist might reduce aversive arousal (white), whereas
opioid antagonist might increase it (black). According to this hypothesis,
drug effects on cognition depend on the baseline level of aversive arousal,
such that an opioid agonist might improve performance in high stress
contexts, yet impair performance under low stress.
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The view that a low opioid drug dose could enhance cog-
nitive performance by reducing aversive arousal also dovetails
with recent rodent work on stress-alleviating properties of
opioids (Valentino & Van Bockstaele, 2015). Endogenous
opioid brain activation in response to stress might similarly
help to prevent stress-induced impairments (Shields et al.,
2016), as indeed suggested in some human (Bandura, Cioffi,
Taylor, & Brouillard, 1988) and animal studies (Laredo et al.,
2015). This view agrees with prior work that shows that cog-
nitive control tasks elicit affective responses (i.e., integral
emotions; Inzlicht et al., 2015), which might drive (mal) adap-
tive behavior (Botvinick, 2007; van Steenbergen et al., 2009)
and which are likely under opioid regulation (van Steenbergen
et al., 2017). Another possibility to consider is that cognitive
improvements after low doses of opioids are caused by in-
creases in appetitive motivation or learning. Such effects are
particularly likely when the task itself involves external re-
wards (Eikemo et al., 2017) or when performance on tasks is
perceived to reflect intelligence or capability. In addition,
tasks perceived to be of high relevance might also generate
internal Bpseudo-rewards^ (Holroyd & Yeung, 2012; Ribas-
Fernandes et al., 2011), in particular when effort is intrinsical-
ly valuable (Inzlicht et al., 2018).
Given these considerations, it is plausible that cognitive
control, just like decision-making, is modulated by opioids
via brain networks involved in valuation, saliency, and moti-
vation, shifting the cost-benefit trade-off, which in turn deter-
mines allocation of cognitive control (Shenhav, Botvinick, &
Cohen, 2013). In addition, prefrontal networks involved in
maintaining task-goal representations might be modulated di-
rectly via binding to its opioid receptors. In line with this
suggestion, a recent PET study observed that high mu-opioid
signaling (lower binding potential) in a ventral region of the
lateral prefrontal cortex was positively related to performance
on theWisconsin Card Sorting Test in a group of patients with
major depressive disorder (Light, Bieliauskas, & Zubieta,
2017). A possible mechanism at a neuronal level could be that
stimulation of mu-opioid receptors suppresses interneuron
spiking and increases glutamate-coded output of prefrontal
neurons at multiple projection targets, which in turn might
engender disorganized control and decision processes
(Baldo, 2016).
Directions for future research
The previous section provided some initial insights into the
role of the mu-opioid system in higher-level cognitive func-
tion. Yet, numerous issues require future investigation. One
unresolved challenge is that opioids might reduce cortical sig-
naling without directly affecting performance in cognitive
tasks, because participants use strategies to compensate for
these deficits (Hockey, 1997). Future studies should include
physiological measures, such as cardiovascular measures
(Gendolla, Wright, & Richter, 2011; Kuipers et al., 2017;
Spruit, Wilderjans, & van Steenbergen, 2018) and task-
evoked pupil dilation (Kahneman, 1973; van der Wel & van
Steenbergen, 2018) to investigate potential compensatory
mechanisms. In addition, behavioral impairments in control
tasks might reflect shifts in motivation instead of reflecting a
cognitive incapability (Kurzban, Duckworth, Kable, &Myers,
2013; Shenhav et al., 2017). As we alluded to earlier, cogni-
tive control shares many processes and brain circuits that also
are important for value-based decision making, and future
studies are warranted to understand the role of opioids in these
processes (Berkman, Hutcherson, Livingston, Kahn, &
Inzlicht, 2017).
Although opioid agonist drugs do not typically produce
strong subjective effects at low doses (Hanks, O’Neill,
Simpson, Wesnes, 1995), changes in self-reported mood and
arousal are typically reported in many of the studies reviewed,
most consistently at higher doses. The evidence for mood
effects from opioid blockade on the other hand, is much less
compelling (Berna et al., 2018; Eippert et al., 2008; Grevert &
Goldstein, 1977). Interestingly, mood induction tasks appear
to modulate endogenous opioid neurotransmission (Koepp
et al., 2009; Prossin et al., 2015; Zubieta et al., 2003). One
important avenue for future research is to understand the role
of affective and motivational states in altered cognitive func-
tion. For example, studies might investigate whether variation
in receptor binding potential or drug-induced changes in sub-
jective state correlate with behavioral outcomes (Light et al.,
2017; Weber et al., 2016). Researchers investigating the effect
of hedonic states on cognitive control and decision making
(Dreisbach & Goschke, 2004; Isen & Means, 1983; van
Steenbergen, Band, & Hommel, 2010; Van Steenbergen,
Band, Hommel, Rombouts, & Nieuwenhuis, 2015) and the
influence of motivation on these processes (Botvinick &
Braver, 2015; Braver et al., 2014; Pessoa, 2009) could use
antagonist drugs to determine the role of endogenous mu-
opioid neurotransmission in these effects. On a related note,
more broadly defined control processes, such as mental flex-
ibility and creativity, often have been related to positive affec-
tive states (Ashby, Isen, & Turken, 1999). It would be inter-
esting to assess the role of the opioid system in these processes
as well (Streufert & Gengo, 1993; Zacny, 1995).
Opioid administration at higher doses can produce other
subjective effects that may influence task performance, such
as nausea, difficulty concentrating, or sedation (Zacny & de
Wit, 2009). Aversive side-effects could counteract a positive
hedonic shift induced by opioid agonists or inflate the nega-
tive shift induced by opioid antagonism. Drowsiness and feel-
ing spaced out from large opioid drug doses could also direct-
ly impact performance on cognitive and value-based tasks.
Such confounds can be avoided by employing smaller drug
doses (counteracting any loss in statistical power, e.g., by
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increasing sample sizes) or by employing active placebo treat-
ments to ensure that drug conditions are matched on relevant
side effects. In addition, future research could draw inspiration
from anecdotal evidence that opioids can induce pain
asymbolia, i.e., intact detection of pain but without the
affective-motivational component (Berthier, Starkstein, &
Leiguarda, 1988). Studies might therefore implement mea-
sures of motivation/detachment to measure the effects of opi-
oid drugs on engagement with cognitive and decision-making
tasks.
Another unresolved question relates to context and coun-
terfactual outcomes. Do opioid drugs modulate high-value
reward processes equally in the presence of punishments, such
as pain or possible economic loss? As recently observed by
Buchel et al. (2018), opioid blockade reduced pleasantness
ratings of erotic stimuli significantly more than ratings of
monetary wins. It is unclear whether the inclusion of highly
salient erotic stimuli reduced the relative value of money dur-
ing the experiment. As for tasks including punishments as
well as rewards, it is possible that mu-opioid stimulation
would cause a shift primarily of aversive stimuli but not re-
wards, because aversive stimuli are typically more salient
(Kahneman & Tversky, 1979). Naloxone increased aversive-
ness of economic loss but not economic gain in Petrovic et al.
(2008). Kut et al. (2011) found effects of naloxone on pain but
not on pleasantness ratings of erotic stimuli. Also, two studies
have reported decreased pleasantness of opioid drug effects
during physical pain (Conley, Toledano, Apfelbaum, &
Zacny, 1997; Zacny, McKay, et al., 1996b; but see Comer,
Sullivan, Vosburg, Kowalczyk, & Houser, 2010). Studies in-
cluding both positive and negative facial expressions provide
mixed evidence, however, with opioid drug effects preferen-
tially observed for negative or positive affective stimuli in
different studies. (Bershad et al., 2016; Loseth et al., 2018;
Syal et al., 2015; Wardle et al., 2016). Moreover, Berna
et al. (2018) reported the largest naloxone reduction in pleas-
antness of the best possible (yet still painful) outcome, indi-
cating that relative relief is opioid-dependent. Well-powered
studies, including both rewarding and aversive outcomes, are
needed to resolve these inconsistencies. In addition, opioid
effects on value-based decision making should also be ad-
dressed during ongoing pain (Gandhi, Becker, &
Schweinhardt, 2013) or other opioid-sensitive aversive states.
Although opioid drugs can exert direct effects on mu-
opioid receptors expressed in the important hubs of the neural
decision-making and cognitive-control networks (Figure 1),
they can also act indirectly via other neurotransmitters. For
example, the canonical disinhibition model of Johnson and
North (1992) proposed that opioid drugs induce reward via
increased dopamine signaling due to opioid inhibition of
GABA interneurons in the ventral tegmental area.More recent
work has shown that we are only at an early stage of under-
standing the exact role of dopamine signaling for opioid drug
effects (Badiani, Belin, Epstein, Calu, & Shaham, 2011; Corre
et al., 2018; Nutt, Lingford-Hughes, Erritzoe, & Stokes,
2015). For instance, mu-opioid receptor activation can have
a net excitatory or net inhibitory effect on VTA neurons de-
pending on a variety of pre- and postsynaptic mechanisms
(Fields &Margolis, 2015). Furthermore, dopamine modulates
cognition via different receptor types and pathways
(Bromberg-Martin, Matsumoto, & Hikosaka, 2010; Cools,
2015), making direct comparisons difficult. The available ev-
idence renders it unlikely that effects of opioid drugs can
simply be explained in terms of dopaminergic modulation
alone. Rodent findings that mu-opioids and dopamine play
functionally different roles in the hedonic and motivational
properties of reward (Berridge, 2007) need further examina-
tion in humans. For instance, some studies are beginning to
manipulate opioids and dopamine pharmacologically using
the same tasks (Porchet et al., 2013; Weber et al., 2016) or
even combining an agonist for one system with an antagonist
for the other (Jayaram-Lindström et al., 2017; Jayaram-
Lindström, Wennberg, Hurd, & Franck, 2004; Roche et al.,
2017).
The mu-opioid system also interacts with other neurotrans-
mitters systems. For example, interactions between opioids
and the locus-coeruleus-norepinephrine system are well-
documented (Arnsten et al., 1981; Chaijale et al., 2013), and
futures studies might investigate whether opioid drugs modu-
late cognitive processing via norepinephrine. There is also
evidence that the endocannabinoid system interacts with opi-
oid mechanisms that support reward (Rowland, Mukherjee, &
Robertson, 2001; Solinas & Goldberg, 2005).
In addition to the literature reviewed, there is increasing
evidence of opioid involvement in psychopathology. For ex-
ample, chronic opioid antagonist administration may increase
cognitive control and decrease the value of reinforcers in dif-
ferent patient groups (Lobmaier, Kunøe, Gossop, & Waal,
2011), and there is some evidence for dysregulation of mu-
opioid receptor function across addictions (Ghitza et al., 2010;
Mick et al., 2016). While chronic opioid misuse has been
associated with maladaptive decisions (Giordano et al.,
2002; Landes, Christensen, & Bickel, 2012), prolonged opi-
oid blockade can reduce craving and drug taking in individ-
uals with substance use disorder (Johnson, 2006; Mouaffak
et al., 2017; Tanum et al., 2017). Interestingly, in addition to
reducing craving and relapse in addiction, opioid blockade
may reduce impulsive behaviors in kleptomania, pathological
gambling, and Bsex addiction^ (Bostwick & Bucci, 2008;
Grant, Kim, & Odlaug, 2009; Johnson, 2006; Lahti, Halme,
Pankakoski, Sinclair, & Alho, 2010; Minozzi et al., 2011;
Porchet et al., 2013; Rukstalis et al., 2005; Stotts, Dodrill, &
Kosten, 2009). In a different line of research, recent work has
suggested that opioid agonists might reduce depressive symp-
toms (Ehrich et al., 2015; Fava et al., 2016; Stanciu, Glass, &
Penders, 2017; Yovell et al., 2016) and influence anhedonia
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(Barch, Pagliaccio, & Luking, 2015; Treadway, Bossaller,
Shelton, & Zald, 2012), providing possible new avenues to
treat patients with mood disorders.
Conclusions
The present review supports a role for the opioid system in
modulating some key aspects of cognitive control and deci-
sion-making. We have shown that the effects of reward-based
decision-making by opioid drugs might be driven by a shift in
valuation processes. At higher doses, opioid agonists can im-
pair performance on neuropsychological executive function
tasks involving coding and logical reasoning. At lower doses
opioids can improve cognitive function, and the working hy-
pothesis proposed suggests that these effects are driven by
opioid-induced reduction of aversive arousal. We hope that
this review provides an initial roadmap for future research to
gain a better understanding of how opioids modulate cogni-
tion, affect, and their interactions.
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